May 20th 2024
During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses why he recommends tagraxofusp-exrs for patients with blastic plasmacytoid dendritic cell neoplasm in need of treatment in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
CTL019 Granted Breakthrough Designation by FDA for DLBCL
April 18th 2017Tisagenlecleucel-T has been granted a breakthrough therapy designation by the FDA for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.
Read More
Treating Melanoma After Immunotherapy and Targeted Therapies
April 17th 2017Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses options for treating melanoma after the use of targeted therapies and immunotherapy.
Watch
New Conditioning Regimens May Prevent Blood Cancer Relapses
April 14th 2017Patients with hematologic malignancies who receive a hematopoietic stem cell transplant (HSCT) still risk treatment failure through relapse. As part of a conditioning regimen prior to allogenic HSCT, strategies are emerging to improve HSCT outcomes by reducing the risk of relapse. Several of these conditioning regimens were reviewed during a satellite symposium to the 2017 BMT Tandem Meetings.
Read More
Locke Details Exciting Results for CAR T Cell Therapy in NHL
April 13th 2017The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel has shown promising results in patients with diffuse large B-cell lymphoma, primary mediastinal lymphoma, and transformed follicular lymphoma, according to findings presented at the 2017 AACR Annual Meeting.
Read More
Higher Dose of Ipilimumab Improves Survival, But Increases Toxicities in Advanced Melanoma
April 12th 2017According to results from a randomized, double-blind, phase III study, patients with stage III or IV melanoma assigned to 10 mg/kg ipilimumab lived longer than patients assigned to a lower dose of the anti-CTLA-4 anticlonal antibody, but at the cost of greater toxicity.
Read More
Finding a Quick, Durable Therapy for Elderly Patients With AML is the Holy Grail, Expert Says
April 12th 2017Andrew Wei, MBBS, PhD, discusses a study which explored the safety and efficacy of the novel BCL-2 inhibitor venetoclax in combination with low-dose cytarabine chemotherapy for treatment-naïve patients over the age of 65 with AML.
Read More
PI3K Inhibitor Copanlisib Shows Promise In Relapsed/Refractory Lymphoma
April 7th 2017A majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib, according to results from the phase II CHRONOS-1 trial.<br />
Read More
CAR T Cell Functionality Found to Correlate With Outcomes for Patients With NHL
April 7th 2017A retrospective analysis presented at the 2017 AACR Annual Meeting found the flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma.
Read More
Encouraging Early Signal Seen With Addition of Coxsackievirus to Ipilimumab in Melanoma
April 7th 2017Adding a formulation of the Coxsackievirus A21 to ipilimumab yielded an overall response rate of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.
Read More
Exploiting DNA Repair Deficiency in IDH-Mutant Brain Tumors Likely an Improved Treatment Strategy
April 6th 2017Mutations in isocitrate dehydrogenase 1 and 2 (<em>IDH1/2</em>) are not the mutations commonly found in cancer cells, according to a presentation from the 2017 AACR Annual Meeting.
Read More
Exploring Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With AML
April 6th 2017Sudipto Mukherjee, MD, assistant staff, Gaussig Cancer Institute, Cleveland Clinic, discusses a study exploring eltrombopag to enhance platelet count recovery in elderly patients with acute myeloid leukemia (AML).
Watch
Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma
April 6th 2017Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma.
Watch
More Than 80% of Patients Respond to CAR T-Cell Therapy in Phase II NHL Trial
April 6th 2017More than 80% of patients with refractory non-Hodgkin lymphoma (NHL) achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (KTE-C19), according to the results of a pivotal phase II trial.
Read More
Nivolumab/Ipilimumab Combo Induces 12% OS Benefit in Melanoma, Updated Phase III Findings Show
April 6th 2017The PD-1 and CTLA-4 inhibitor combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced a 12% reduction in the risk of death versus nivolumab monotherapy in patients with treatment-naïve advanced melanoma.
Read More
Brentuximab Vedotin Benefits Offset Risk of Peripheral Neuropathy, Patients Say
April 3rd 2017Patients with lymphoma who are treated with brentuximab vedotin often experience peripheral neuropathy as an adverse event and potentially dose-limiting toxicity. A novel study has shown that, despite the prevalence of this toxicity, these patients report that the better outcomes yielded from treatment with brentuximab vedotin outweigh the risk of neuropathy.
Read More
sBLA for Full Approval of Blinatumomab in ALL Granted FDA's Priority Review
March 30th 2017The FDA has granted a priority review to a supplemental biologics license application (sBLA) supporting the conversion of the accelerated approval of blinatumomab (Blincyto) to a full approval as a treatment for patients with Philadelphia chromosome-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
Read More
Comparing Hydroxyurea and Pegylated Interferon-Alpha-2a in PV and ET
March 29th 2017John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a (Pegasys) with hydroxyurea in the treatment of patients with high-risk polycythemia vera (PV) and essential thrombocythemia (ET).
Watch